An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
研究概览
详细说明
This Phase 2, multi-center, open-label extension study is designed to assess the long-term safety, tolerability, and functional efficacy of weekly intravenous doses of BMN 351 administered to participants with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping in the Phase 1/2 study, 351-201. Up to 18 participants ages 4 through 23 at baseline will enroll in the trial after completing 351-201.
The first visit for this study is the same as the final visit of 351-201. To be eligible for this study, potential participants must satisfy the eligibility criteria described in the protocol.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Turkey
-
Istanbul、Turkey、土耳其(türkiye)
- Yeditepe University Kosuyolu Hospital
-
-
-
-
Italy
-
Milan、Italy、意大利
- Fondazione Serena ETS - Centro Clinico NeMO Milano
-
Rome、Italy、意大利
- UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
-
-
-
-
United Kingdom
-
London、United Kingdom、英国、WC1N 3JH
- Great Ormond Street Hospital NHS Foundation Trust
-
-
-
-
Netherlands
-
Leiden、Netherlands、荷兰、2333 ZA
- Leids Universitair Medisch Centrum
-
-
-
-
Spain
-
Seville、Spain、西班牙、41013
- Hospital Viamed Santa Angela De la Cruz
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Participants must have completed 351-201 without permanent discontinuation of the investigational medicinal product (IMP) or withdrawal from the study
Currently receiving treatment with oral corticosteroids, on a stable dose regimen during 351-201, and must remain on a consistent dose regimen throughout 351-202 or 351-203 except for modifications to accommodate changes in weight
- Transition to the equivalent dose of vamorolone is permitted in 351-202 where approved in participating countries.
- Willing and able to adhere to the study visit schedule and other protocol requirements
Willing to use contraception (sexually mature males) throughout the study and for 90 days after the final dose, if sexually active
- Contraceptive use by males should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Willing and able to provide written assent (if required by local regulations or the IRB/IEC) after the nature of the study has been explained and prior to performance of any research-related procedure
- Willing and able to provide written, signed informed consent as parent or guardian after the nature of the study has been explained and prior to performance of any research-related procedure
Exclusion Criteria:
- Have known coagulation disorder
Are taking any prohibited medications
- any approved exon skipping therapy within 12 weeks prior to baseline or with any gene therapy for the treatment of DMD at any time
- anti-coagulants, anti-thrombotics, or anti-platelet agents
- immunosuppressants
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:BMN 351
Participants from 351-201 enrolling in 351-202 will initially receive BMN 351 at the dose level at which they completed 351-201.
Once all 351-201 participants have completed their Week 25 visit in 351-202, available safety and PD data will be analyzed and a single optimal dose level will be selected for 351-202.
All participants from 351-201 will transition to that dose level at their next applicable visit.
|
Anti-sense Oligonucleotide BMN 351 will be administered intravenously
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To assess the long-term safety and tolerability of BMN 351 in participants with DMD
大体时间:Through study completion, at least 1 year
|
The safety and tolerability of BMN 351 will be assessed based on the incidence of adverse and serious adverse events.
|
Through study completion, at least 1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To evaluate the effect of BMN 351 on physical function
大体时间:Change from baseline and subsequent 24-week incremental visits
|
Timed 4 stair climb (4SC) will be assessed at the specified visits and compared to individual baseline and external controls
|
Change from baseline and subsequent 24-week incremental visits
|
|
To evaluate the effect of BMN 351 on physical function
大体时间:Change from baseline and subsequent 24-week incremental visits
|
SV95C will be assessed at the specified visits and compared to individual baseline and external controls
|
Change from baseline and subsequent 24-week incremental visits
|
|
To evaluate the effect of BMN 351 on physical function
大体时间:Change from baseline and subsequent 24-week incremental visits
|
PUL 2.0 will be assessed at the specified visits and compared to individual baseline and external controls
|
Change from baseline and subsequent 24-week incremental visits
|
|
To evaluate the effect of BMN 351 on physical function
大体时间:Change from baseline and subsequent 24-week incremental visits
|
North Star Ambulatory Assessment (NSAA) will be assessed at the specific visits and compared to individual baseline and external controls
|
Change from baseline and subsequent 24-week incremental visits
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To evaluate the trough plasma concentration of BMN 351
大体时间:Baseline, Week 13, Week 25, Week 37, Week 49
|
Serial predose measurements of trough plasma PK
|
Baseline, Week 13, Week 25, Week 37, Week 49
|
|
To evaluate the immune response to BMN 351
大体时间:Change from baseline and subsequent 24-week incremental visits
|
Anti-BMN 351 antibodies and Anti-dystrophin antibodies
|
Change from baseline and subsequent 24-week incremental visits
|
|
To evaluate lung function longitudinally for participants ages 7 and above
大体时间:Change from baseline to subsequent 24-week incremental visits
|
Forced Expiratory Volume in 1 second (FEV1) for participants ages 7 and above
|
Change from baseline to subsequent 24-week incremental visits
|
|
To evaluate lung function longitudinally for participants ages 7 and above
大体时间:Change from baseline to subsequent 24-week incremental visits
|
Forced Vital Capacity (FVC) for participants ages 7 and above
|
Change from baseline to subsequent 24-week incremental visits
|
|
To evaluate lung function longitudinally for participants ages 7 and above
大体时间:Change from baseline to subsequent 24-week incremental visits
|
Peak Cough Flow (PCF) for participants ages 7 and above
|
Change from baseline to subsequent 24-week incremental visits
|
|
To evaluate lung function longitudinally for participants ages 7 and above
大体时间:Change from baseline to subsequent 24-week incremental visits
|
Maximal Inspiratory Pressure (MIP) for participants ages 7 and above
|
Change from baseline to subsequent 24-week incremental visits
|
|
To evaluate lung function longitudinally for participants ages 7 and above
大体时间:Change from baseline to subsequent 24-week incremental visits
|
Maximal Expiratory Pressure (MEP) for participants ages 7 and above
|
Change from baseline to subsequent 24-week incremental visits
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 351-202
- 2024-511656-41-00 (克蒂斯)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.